ProCE Banner Activity

MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy

Slideset Download
Conference Coverage
Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology